| Literature DB >> 25716347 |
Stefan Werner1, Benedikt Brors2, Julia Eick1, Elsa Marques3, Vivian Pogenberg4, Annabel Parret4, Dirk Kemming5, Antony W Wood6, Henrik Edgren7, Hans Neubauer8, Thomas Streichert9, Sabine Riethdorf1, Upasana Bedi1, Irène Baccelli10, Manfred Jücker11, Roland Eils12, Tanja Fehm8, Andreas Trumpp10, Steven A Johnsen1, Juha Klefström3, Matthias Wilmanns4, Volkmar Müller13, Klaus Pantel1, Harriet Wikman14.
Abstract
UNLABELLED: Regulatory pathways that drive early hematogenous dissemination of tumor cells are insufficiently defined. Here, we used the presence of disseminated tumor cells (DTC) in the bone marrow to define patients with early disseminated breast cancer and identified low retinoic acid-induced 2 (RAI2) expression to be significantly associated with DTC status. Low RAI2 expression was also shown to be an independent poor prognostic factor in 10 different cancer datasets. Depletion of RAI2 protein in luminal breast cancer cell lines resulted in dedifferentiation marked by downregulation of ERα, FOXA1, and GATA3, together with increased invasiveness and activation of AKT signaling. Functional analysis of the previously uncharacterized RAI2 protein revealed molecular interaction with CtBP transcriptional regulators and an overlapping function in controlling the expression of a number of key target genes involved in breast cancer. These results suggest that RAI2 is a new metastasis-associated protein that sustains differentiation of luminal breast epithelial cells. SIGNIFICANCE: We identified downregulation of RAI2 as a novel metastasis-associated genetic alteration especially associated with early occurring bone metastasis in ERα-positive breast tumors. We specified the role of the RAI2 protein to function as a transcriptional regulator that controls the expression of several key regulators of breast epithelial integrity and cancer. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25716347 DOI: 10.1158/2159-8290.CD-14-1042
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397